Tag Archives: Pharmaceutical gets approval for trials of COVID-19 medicine

SEOUL: South Korean drugmaker Daewoong Pharmaceutical said on Monday that it had received regulatory approval for Phase 1 clinical trials of its anti-parasitic niclosamide drug to treat COVID-19 patients. The approval comes after the company in August received Indian regulatory approval to test the drug in Phase 1 trials. The company confirmed the safety of the drug in its latest …

Read More »